Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
- Dr. Sonia Quaratino, current EVP, Chief Medical Officer is appointed to the Executive Board.
- Arvind Sood joins the Company in a newly created position of Executive Vice President, Innate Pharma SA and President of US Operations.
- “We are taking steps to position Innate Pharma for future success by significantly strengthening our Executive Board now comprising Yannis, Sonia and Arvind,” said Hervé Brailly, interim Chief Executive Officer.